Navigation Links
Optimer Reports Fourth Quarter and Fiscal Year 2011 Financial Results
Date:3/7/2012

idiary and appointed a country manager to support efforts to sell DIFICID directly into Canadian markets, if approved. In addition, the company filed a New Drug Submission to Health Canada for DIFICID for the treatment of CDAD and was granted a priority review from the Canadian authorities.
  • In July 2011, Optimer announced the commercial launch of DIFICID tablets for the treatment of CDAD in patients 18 years of age and older.
  • In May 2011, the U.S. Food and Drug Administration approved Optimer's antibacterial drug DIFICID® (fidaxomicin) tablets for the treatment of CDAD in adults 18 years of age and older.
  • In April 2011, Optimer entered into a co-promotion agreement with Cubist Pharmaceuticals to market DIFICID in the U.S. in an effort to accelerate the DIFICID launch. Cubist's 180 hospital-based sales reps combined with Optimer's 100 sales reps are jointly promoting DIFICID to physicians, hospitals, long-term care facilities and other healthcare institutions.
  • In February 2011, Optimer entered into a collaboration agreement with Astellas Pharma Europe Ltd. to develop and commercialize DIFICLIR in Europe and certain other countries in the Middle East, Africa, and the Commonwealth of Independent States.  Under the agreement, Optimer is eligible to receive milestone payments of up to approximately $224 million and of which $69.2 million was received upfront, and a $53.6 million milestone was recorded in the fourth quarter related to the EMA approval. The agreement provides Optimer tiered double-digit royalty payments on net sales of DIFICLIR in the Astellas territories.
  • In February 2011, DIFICID North American Phase 3 trial results were published in The New England Journal of Medicine in an article titled, "Fidaxomicin versus Vancomycin for Clostridium difficile Infection," in the February 3, 2011&#
    '/>"/>

  • SOURCE Optimer Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and FY 2011 Financial Results
    2. Optimer Pharmaceuticals to Present at the 32nd Annual Cowen Health Care Conference
    3. Optimer Pharmaceuticals Provides Update on DIFICID® (fidaxomicin) Tablets Launch
    4. Optimer Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
    5. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    6. Optimer Pharmaceuticals to Present at BioCentury Newsmakers Conference
    7. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
    8. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
    9. Optimer Pharmaceuticals DIFICID Featured in 11 Presentations at 51st ICAAC
    10. Optimer Pharmaceuticals to Present at September 2011 Investor Conferences
    11. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/23/2015)... , January 23, 2015 Heptares Therapeutics, the ... to announce that the Malcolm Campbell Memorial Prize ... (Vice President of Chemistry), Fiona Marshall (Chief Scientific ... Officer and co-founder) for the seminal contributions to GPCR drug ...
    (Date:1/22/2015)... DIEGO, Jan. 22, 2015  ResMed Inc. (NYSE: RMD ... 2014. Revenue for the quarter was $423.0 million, a 10 ... (a 14 percent increase on a constant currency basis). Net ... to the quarter ended December 31, 2013. Diluted earnings per ...
    (Date:1/22/2015)... Calif. , Jan. 22, 2015 Increasing sophistication ... continued consolidation of localization purchasing in 2015, says ... According to a recent study by market research firm ... a single-source solution for their translation and localization needs. ...
    Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
    ... NEW YORK, Nov. 3, 2011 Intellect Neurosciences, ... the discovery and development of disease-modifying therapeutic agents ... diseases announced today that it has filed a ... its antibody methods application Serial  No. 10/084,380, one ...
    ... 2011 Savient Pharmaceuticals, Inc. (NASDAQ: SVNT ) ... ended September 30, 2011, which reflect the Company,s continuing investment ... quarter with $202.7 million in cash and short-term investments, a ... quarter of 2011, the Company had a net loss of ...
    Cached Medicine Technology:Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 2Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application 3Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 2Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 3Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 4Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 5Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 6Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results 7
    (Date:1/22/2015)... California (PRWEB) January 22, 2015 The City of ... at 10 a.m., to commemorate the 42nd anniversary of the Supreme ... States. , “It’s been 42 years since the Roe vs. Wade ... is still as present as ever,” said City of West Hollywood ...
    (Date:1/22/2015)... is a seasoned and trusted leader who consistently delivers trendy ... have it lead the wedding dress industry into the future. ... for the global market. , “The CEO of VogueQueen is ... on continuing the goal of operational excellence and giving back ...
    (Date:1/22/2015)... 23, 2015 AngelWeddingDress, the premier women’s ... maternity wedding dresses. View website of AngelWeddingDress.com ... for maternity wedding dresses online for a bridal party. ... high quality for them. Its maternity wedding dresses are ...
    (Date:1/22/2015)... New York (PRWEB) January 22, 2015 ... after Fresenius Medical Care recalled its GranuFlo and NaturaLyte ... multidistrict litigation underway in U.S. District Court, District of ... dated January 20th, the Court has remanded a case ...
    (Date:1/22/2015)... January 22, 2015 Joan Lunden, award-winning ... speaker at the upcoming 32nd Annual Miami Breast ... Physicians’ Education Resource®, LLC (PER®) , shares that “a ... gone undetected if she had not followed up her ...
    Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
    ... Scientific Pioneers Invest in Evolving Field of Protein ... Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) and Harvard ... innovative collaboration,agreement to pursue a research program in ... field of cancer biology. Under the terms of ...
    ... throughout Minnesota, MINNEAPOLIS, Jan. 31 A ... 76 percent of Minnesotans support the,statewide smoke-free law, ... provides evidence of strong support among all leading,demographics, ... gender. The survey was conducted by Minneapolis research,firm ...
    ... - New Information Strengthens Community,s Demand to Save St. ... ... Sutter Health told the San,Francisco Chronicle in a January 27 article the ... St. Luke,s,Hospital, the South of Market facility they are trying to close:, ...
    ... The Company,s first acne product enters the ... Jan. 30 Skinvisible, Inc. (OTC,Bulletin Board: ... company focused on formulating and enhancing patented,dermatology ... announced it has signed an exclusive licensing ...
    ... Survey of User Satisfaction puts IDC on top ... /PRNewswire-FirstCall/ - IDC (Imaging Dynamics,Company, Ltd.) (TSX: IDL), ... today announced that for the third consecutive,quarter it ... digital,detector radiography systems among 11 vendors in the ...
    ... N.Y., Jan. 30 Moog Inc. (NYSE:,MOG.A and MOG.B) ... John,Scannell, CFO, will present at the 29th Annual Cowen ... 2008 at 11:10 a.m. EST., Listeners can access ... . Please allow 15 minutes prior,to the call to ...
    Cached Medicine News:Health News:Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology 2Health News:Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology 3Health News:Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology 4Health News:Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology 5Health News:Millennium and Harvard Medical School Sign Cooperative Agreement for Research in Novel Field of Cancer Biology 6Health News:New Survey Finds 76 Percent of Minnesotans Support Smoke-Free Law 2Health News:Skinvisible Announces Licensing Agreement for Adapalene 2Health News:Skinvisible Announces Licensing Agreement for Adapalene 3Health News:IDC Digital radiography systems Ranked #1 for third consecutive quarter 2
    ... offer a wide range of storage capacities. ... storage platform to agitate smoothly, eliminating the ... and squeak. Sturdy, one-piece perforated drawers with ... for your platelets., ,i.Series platelet agitators feature ...
    Platelet agitator....
    Reciprocating shaker specifically for platelet bags....
    ... the quantitative determination of ... serum. Progesterone EIA ... principle of competitive binding ... test specimen and progesterone-HRP ...
    Medicine Products: